Pharmaceuticals

The architect of HUMIRA's launch and Horizon's $28B sale is now shaping the next wave of drug companies from within private equity. What does it mean?

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Amble Health's new program offers 50% off weight loss drugs, but it requires patients to pay cash and potentially use non-FDA-approved medications.

Alcami acquires Tjoapack, creating a transatlantic CDMO. The deal, orchestrated by owner Ampersand Capital, signals a major shift in pharma services.

With six new collaborations, the life science leader aims to tame data complexity and accelerate discovery by creating a single, integrated software ecosystem.

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

With its 100th study launch and a perfect client retention rate, Atreo's agile RTSM platform is challenging the rigid, slow pace of traditional trial tech.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

Jeito Capital appoints top talent and BD partners, signaling a strategic shift in biopharma investing where deep operational expertise is now king.